Article

Computational pharmacogenomics screen identifies synergistic statin-compound combinations as anti-breast cancer therapies

2020-09-09

Abstract excerpt

Statins are a family of FDA-approved cholesterol-lowering drugs that inhibit the rate-limiting enzyme of the metabolic mevalonate pathway, which have been shown to have anti-cancer activity. As therapeutic efficacy is increased when drugs are used in combination, we sought to identify agents, like dipyridamole, that potentiate statin-induced tumor cell death. As an antiplatelet agent dipyridamole will not be suita...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1d0b20ab-6ecb-5eef-9722-3ff595793063
DOI: 10.1101/2020.09.07.286922

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Computational pharmacogenomics screen identifies synergistic statin-compound combinations as anti-breast cancer therapiesDOI 10.1101/2020.09.07.286922Read

Computational pharmacogenomic screen identifies drugs that phenocopy dipyridamole and potentiate anti-breast cancer activity of statinsSemantic proximity Read

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read

Synergistic drug combinations from electronic health records and gene expressionSemantic proximity Read

Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read

MULTISCALE ANALYSIS AND VALIDATION OF EFFECTIVE DRUG COMBINATIONS TARGETING DRIVER KRAS MUTATIONS IN NON-SMALL CELL LUNG CANCERSemantic proximity Read

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathwaysSemantic proximity Read

The molecular basis of the anticancer effect of statinsSemantic proximity Read

Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell deathSemantic proximity Read

Rational Discovery of Dual-Action Multi-Target Kinase Inhibitor for Precision Anti-Cancer Therapy Using Structural Systems PharmacologySemantic proximity Read

Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposingSemantic proximity Read

Methods for High-Throughput Drug Combination Screening and Synergy ScoringSemantic proximity Read

Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinationsSemantic proximity Read